Adalimumab-induced pulmonary sarcoidosis not progressing upon treatment with etanercept

초록

Tumor necrosis factor alpha (TNF-alpha) inhibitors effectively treat sarcoidosis, but can, paradoxically, induce sarcoidosis. The TNF-alpha inhibitor etanercept is most commonly associated with paradoxical sarcoidosis, which has previously been reported to be resolved by adalimumab. However, we describe the case of a patient with ankylosing spondylitis and adalimumab-induced sarcoidosis not aggravated by switching to etanercept, thus indicating that etanercept could be a treatment option for patients who develop paradoxical sarcoid-like reactions after treatment with other TNF-alpha inhibitors.

키워드